HRMY Harmony Biosciences Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1802665 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY19.8%
TTM net income YoY-3.8%
TTM EPS YoY-4.7%
Revenue 3-yr CAGR22.2%
Net income 3-yr CAGR5.8%
Margins
Gross margin74.0%
Operating margin22.2%
Net margin18.1%
FCF margin—
EBITDA margin—
Returns
ROE18.7%
ROA13.3%
ROIC (approx.)36.1%
Asset turnover0.74x
Leverage & solvency
Liabilities / assets27.5%
Debt / equity0.14x
Current ratio3.44x
Interest coverage16.99x
Cash quality & payout
Operating cash flow / net income1.81x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $268.92M | $261.28M | $215.39M | $243.78M | $239.46M | $200.49M | $184.73M | $201.27M |
| Cost of revenue | $80.69M | $63.20M | $44.51M | $68.55M | $59.65M | $38.15M | $31.99M | $54.41M |
| Gross profit | $188.23M | $198.08M | $170.88M | $175.23M | $179.81M | $162.34M | $152.74M | $146.86M |
| R&D expense | $71.66M | $46.60M | $69.38M | $49.93M | $54.96M | $50.16M | $34.54M | $34.67M |
| SG&A expense | $27.65M | $28.05M | $32.51M | $57.56M | $29.81M | $33.92M | $31.24M | $28.86M |
| Operating income | $54.20M | $89.32M | $37.29M | $38.56M | $65.49M | $48.18M | $56.24M | $55.73M |
| Interest expense | $3.06M | $3.07M | $3.23M | $3.55M | $3.62M | $3.65M | $3.84M | $4.21M |
| Pretax income | $59.25M | $93.27M | $39.69M | $40.76M | $67.49M | $49.64M | $57.18M | $56.16M |
| Income tax | $11.05M | $17.83M | $7.20M | $18.27M | $16.62M | $9.86M | $11.62M | $6.68M |
| Net income | $48.20M | $75.43M | $32.49M | $22.49M | $50.87M | $39.78M | $45.56M | $49.48M |
| EBITDA | $54.20M | $89.32M | $37.30M | — | $65.49M | $48.19M | $56.25M | $55.73M |
| EPS (basic) | 0.83 | 1.30 | 0.56 | — | 0.88 | 0.69 | 0.79 | — |
| EPS (diluted) | 0.81 | 1.28 | 0.55 | — | 0.87 | 0.68 | 0.78 | — |
| Weighted avg. shares (diluted) | 59.68M | 58.76M | 58.78M | — | 58.72M | 58.43M | 58.52M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $647.10M | $549.77M | $589.40M | $752.50M | $647.27M | $546.32M | $489.27M | $453.27M |
| Short-term investments | $124.04M | $118.02M | $51.52M | $22.84M | $25.58M | $19.22M | $17.95M | $14.19M |
| Receivables | $127.74M | $111.00M | $108.22M | $96.79M | $100.65M | $92.98M | $105.97M | $83.03M |
| Inventory | $5.87M | $6.36M | $5.28M | $5.36M | $6.88M | $6.10M | $6.38M | $7.20M |
| Current assets | $934.83M | $814.33M | $778.82M | $907.01M | $838.80M | $691.35M | $642.69M | $579.25M |
| PP&E, net | — | — | — | — | $1.44M | $1.38M | $1.38M | $1.26M |
| Intangibles | $71.53M | $77.50M | $83.46M | $89.42M | $95.38M | $101.34M | $107.30M | $113.26M |
| Total assets | $1.48B | $1.37B | $1.27B | $1.27B | $1.21B | $1.11B | $1.06B | $999.20M |
| Current liabilities | $271.54M | $234.07M | $217.34M | $252.13M | $223.40M | $180.13M | $175.12M | $175.08M |
| Short-term debt | $20.00M | $20.00M | $20.00M | $20.00M | $20.00M | $18.75M | $17.50M | $16.25M |
| Long-term debt | $129.10M | $133.96M | $138.81M | $143.66M | $148.51M | $153.34M | $158.18M | $163.02M |
| Total debt | $149.10M | $153.96M | $158.81M | $163.66M | $168.51M | $172.09M | $175.68M | $179.27M |
| Total liabilities | $406.01M | $373.84M | $361.48M | $401.41M | $373.10M | $334.93M | $335.01M | $340.05M |
| Shareholders' equity | $1.07B | $999.24M | $910.35M | $870.22M | $835.12M | $773.08M | $720.52M | $659.15M |
| Net debt | -$498.00M | -$395.81M | -$430.58M | -$588.84M | -$478.76M | -$374.23M | -$313.59M | -$274.00M |
| Shares outstanding | 58.72M | 58.12M | 57.87M | 57.73M | 57.60M | 57.54M | 57.39M | 57.14M |
| Cash flow statement | ||||||||
| Operating cash flow | $76.69M | $92.43M | $27.76M | $126.15M | $108.73M | $79.33M | $33.99M | $75.56M |
| Capital expenditure | — | — | — | $107,000 | $71,000 | $4,000 | $128,000 | $513,000 |
| Free cash flow | — | — | — | $126.04M | $108.66M | $79.32M | $33.86M | $75.05M |
| Investing cash flow | $7.68M | -$131.50M | -$183.65M | -$17.63M | -$4.79M | -$19.59M | $2.36M | -$7.19M |
| Financing cash flow | $12.96M | -$558,000 | -$7.22M | -$3.02M | -$3.00M | -$2.69M | -$352,000 | -$2.74M |
| Depreciation & amortization | $7,000 | $7,000 | $7,000 | — | $7,000 | $6,000 | $7,000 | $6,000 |
| Stock-based compensation | $8.13M | $9.58M | $10.62M | $9.97M | $10.82M | $11.39M | $12.50M | $10.07M |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.